Bogart Wealth LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bogart Wealth LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Buy	46 +7	+18%	+$2.11K	﹤0.01%	912
2026 Q1	$12.9K	Buy	39 +3	+8%	+$1.02K	﹤0.01%	853
2025 Q4	$14.3K	Buy	36 +1	+3%	+$443	﹤0.01%	774
2025 Q3	$16K	Hold	35	–	–	﹤0.01%	721
2025 Q2	$11.4K	Hold	35	–	–	﹤0.01%	769
2025 Q1	$9.45K	Buy	35 +4	+13%	+$1.03K	﹤0.01%	767
2024 Q4	$7.29K	Hold	31	–	–	﹤0.01%	802
2024 Q3	$8.53K	Sell	31 -5	-14%	-$1.3K	﹤0.01%	729
2024 Q2	$8.75K	Hold	36	–	–	﹤0.01%	696
2024 Q1	$5.38K	Hold	36	–	–	﹤0.01%	752
2023 Q4	$6.89K	Hold	36	–	–	﹤0.01%	689
2023 Q3	$6.38K	Hold	36	–	–	﹤0.01%	672
2023 Q2	$6.84K	Hold	36	–	–	﹤0.01%	646
2023 Q1	$7.21K	Hold	36	–	–	﹤0.01%	650
2022 Q4	$8.55K	Hold	36	–	–	﹤0.01%	582
2022 Q3	$7K	Hold	36	–	–	﹤0.01%	617
2022 Q2	$5K	Hold	36	–	–	﹤0.01%	626
2022 Q1	$6K	Hold	36	–	–	﹤0.01%	547
2021 Q4	$6K	Hold	36	–	–	﹤0.01%	525
2021 Q3	$7K	Hold	36	–	–	﹤0.01%	495
2021 Q2	$6K	Hold	36	–	–	﹤0.01%	488
2021 Q1	$5K	Buy	+36	New	+$5.42K	﹤0.01%	461

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bogart Wealth LLC's ALNY Position: Q2 2026 in Review

Bogart Wealth LLC increased its Alnylam Pharmaceuticals (ALNY) stake by 18% in Q2 2026, buying an estimated $2.11K and bringing the position to 46 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Bogart Wealth LLC first reported a position in ALNY in Q1 2021 and has held it in 22 quarters since. The position peaked at $16K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Bogart Wealth LLC held 46 shares of Alnylam Pharmaceuticals worth $13.8K as of Q2 2026.
Bogart Wealth LLC bought 7 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.11K.
Alnylam Pharmaceuticals made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #912 holding.
Bogart Wealth LLC first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Bogart Wealth LLC's Alnylam Pharmaceuticals position peaked at $16K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.